DNA synthesis is vital to several processes in biopharmaceutical innovation, including the development of gene therapies, CRISPR gene editing, antisense oligonucleotides and RNA therapies. The need ...

Despite these advances, the synthesis of DNA nanostructures has remained a largely manual and time-consuming process. Traditional approaches often require the precise mixing of hundreds of unique DNA ...

Nowadays, there's lots of buzz about spectacular new medical treatments such as personalised cancer therapy with modified immune cells or antibodies. Such treatments, however, are very complex and ...

There’s been this dream for decades. What if we could just print out an entire gene directly, one base at a time? —Daniel Lin-Arlow, Ansa Biotechnologies As scientists set their sights on cell and ...

DNA is the raw material of modern medicine yet is the only part of drug development not accessible at the lab bench. DNA synthesis, the first step in most biological workflows including gene synthesis ...

DNA has tremendous potential as a data storage medium, but the process of synthesizing DNA from scratch is time-consuming. It has to be done one nucleotide at a time in a specific sequence. New ...

Every researcher knows the frustration: your groundbreaking experiment is on hold because the DNA sequence you need is "unmanufacturable". Or worse, after weeks of waiting, the oligos arrive with ...

There’s an old saying about a dollar waiting on a dime. In other words, a monumental endeavor may become stuck at some point if a key preliminary element remains unavailable. The saying could be ...

Demand for synthetic DNA is growing across multiple industries including cell and gene therapy development and biomanufacturing. Coupled with that growth is a need for genetic constructs that can, in ...

Ansa Biotechnologies hauled in a total of $54.4 million in an oversubscribed series B round of financing that will be used to expand the company’s DNA synthesis production capacity in the U.S. The San ...